Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations canakinumab - IL-1 beta inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03631199 CANOPY-1 (CACZ885U2301) 1st Line Non-small cell lung cancer (NSCLC) Phase 3 627 Safety run-in part: Incidence of dose limiting toxicities Double-blind, randomized, placebo-controlled part: Progression free survival (PFS) Overall survival (OS) Canakinumab or matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy Patients with: Histologically confirmed Stage IIIB, IV NSCLC with no prior systemic anticancer therapy Squamous and non-squamous NSCLC No EGFR mutation and ALK rearrangement H2-2021 Johnson B et al. Presented at AACR-NCI-EORTC 2019 (safety run-in) Planned abstract submission to AACR 2022 115 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation